The FDA approved linerixibat (Lynavoy) as the first drug indicated for cholestatic pruritus stemming from primary biliary ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the most promising stocks under $100 to buy. On March 16, Mirum ...

Learn why primary biliary cholangitis (PBC) causes intense itching, and explore treatment options, management tips, and skin-care strategies for relief.

The FDA has approved the first medication for cholestatic pruritus in adult patients with primary biliary cholangitis.The approval of linerixibat (Lynavoy, GSK) — an ileal bile acid transporter ...

GSK’s Lynavoy receives US FDA approval for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Saturday, March 21, 2026, 11:00 Hrs [IST] GSK plc announ ...

The double-blind, randomised, placebo-controlled trial will assess the efficacy and safety of Livmarli in both children and ...

Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.

Add Yahoo as a preferred source to see more of our stories on Google. Zyrtec and Xyzal are approved by the FDA for over-the-counter use. You can find plenty of Reddit threads with folks discussing ...

DelveInsight's Chronic Pruritus Market Insights report includes a comprehensive understanding of current treatment practices, chronic pruritus emerging drugs, market share of individual therapies, and ...

Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...